Allergy Therapeutics PLC Investor and analyst site visits
June 27 2017 - 2:01AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
27 June 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Investor and analyst site visits
27 June 2017 Allergy Therapeutics plc (AIM:AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, is hosting a site visit at its corporate headquarters for
sell-side analysts today and institutional investors tomorrow.
The site visits will be hosted by Manuel Llobet, Chief Executive
Officer, Nick Wykeman, Finance Director, and Murray Skinner, Chief
Scientific Officer and will include presentations by the Group's
key opinion leaders who are world-leading in their fields of
expertise, including Professor Lawrence DeBuske, Clinical Professor
of Medicine at the George Washington University School of Medicine,
and Professor Dr Matthias Kramer, International Medical Director of
Allergy Therapeutics.
During the visits, attendees will be provided with an update on
the Group's market-leading businesses, markets, strategy and
pipeline.
No inside information will be disclosed. The presentations will
be available on the Group's website from 28 June 2017.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Group sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries. Its
broad pipeline of products in clinical development include vaccines
for grass, tree and house dust mite, and peanut allergy, malaria
and influenza vaccines in pre-clinical development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group employs c.495 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKADDOBKDQAB
(END) Dow Jones Newswires
June 27, 2017 02:01 ET (06:01 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024